Description
CJC-1295 with DAC incorporates a drug affinity complex that promotes albumin binding, substantially extending the compound’s half-life relative to the non-DAC form. It acts as a long-acting GHRH receptor agonist in research settings.
Investigations have examined sustained growth hormone elevation, GHRH receptor signaling, and IGF-1 responses over extended intervals in cell and rodent systems. Its prolonged activity makes it a useful contrast to short-acting GHRH analogs.
Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.
Reviews
There are no reviews yet.